Home / Private raises / Ansa Biotechnologies, Inc.
Ansa Biotechnologies, Inc.
Biotechnology · Emeryville, California · $54.4M sold across 1 offering
Form D filings (1)
| Filed | Form | Sold | Offered | Investors | Exemption | Securities | First sale | |
|---|---|---|---|---|---|---|---|---|
| 2026-11-18 | D (new) | $54.4M | $71.9M | 18 | 506(b) | Equity | Oct 16 | SEC ↗ |
An update (D/A) restates the running total of its offering, so the total above counts each offering's latest figure once.
Issuer
| Industry | Biotechnology |
| Located | Emeryville, California |
| Entity | Corporation |
| Incorporated | Delaware |
| SEC CIK | 1816722 |
People named in the latest filing
| Name | Role |
|---|---|
| Jason T Gammack | Executive Officer, Director |
| Daniel Lin-Arlow | Executive Officer, Director |
| Yanniv Dorone | Director |
| Brad Crutchfield | Director |
| Nate Cornell | Director |
| Nick Naclerio | Director |
| Chenny Zhang | Director |
| Matthias Arenskotter | Executive Officer |
| Geoff Hamilton | Executive Officer |
| Sebastian Palluk | Executive Officer |
Names and roles as filed with the SEC. Addresses are not shown.
Source: SEC EDGAR Form D filings. Amounts are self-reported by the issuer. Not investment advice.
How are we doing?
